Trastuzumab rezetecan
Trastuzumab rezetecan (SHR-A1811) is a HER2-targeting antibody-drug conjugate (ADC) . Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408) . Trastuzumab rezetecan can be used for research in HER2-positive breast cancer[1].
Product Specifications
CAS Number
[2924909-11-3]
Product Name Alternative
SHR-A1811
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; EGFR
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/trastuzumab-rezetecan.html
Purity
98.61
Smiles
[Trastuzumabrezetecan]
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
Phase 3
Isoform
ErbB2/HER2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral mouse Hectd4 shRNA (UAS) - Lentiviral mouse Hectd4 shRNA (UAS, iRFP) (100)